UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051931
Receipt number R000059251
Scientific Title Evaluation of antimicrobial and surgical treatment for MRSA (methicillin-resistant Staphylococcus aureus) endocarditis.
Date of disclosure of the study information 2023/08/17
Last modified on 2023/08/17 14:15:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of antimicrobial and surgical treatment for MRSA (methicillin-resistant Staphylococcus aureus) endocarditis.

Acronym

Evaluation of antimicrobial and surgical treatment for MRSA (methicillin-resistant Staphylococcus aureus) endocarditis.

Scientific Title

Evaluation of antimicrobial and surgical treatment for MRSA (methicillin-resistant Staphylococcus aureus) endocarditis.

Scientific Title:Acronym

Evaluation of antimicrobial and surgical treatment for MRSA (methicillin-resistant Staphylococcus aureus) endocarditis.

Region

Japan


Condition

Condition

Infective endocarditis (IE) due to MRSA

Classification by specialty

Cardiology Infectious disease Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We investigate the characteristics of patients with MRSA IE in Japan, antimicrobial therapy, and to determine the actual rate of surgical treatment and patient prognosis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

30-day and in-hospital mortality

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with a definite diagnosis of MRSA-IE from January 2015 to April 2019 were included.

Key exclusion criteria

-Patients under the age of 16.
-Patients with Healed IE.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Kotaro
Middle name
Last name Mitsutake

Organization

Saitama Medical University International Medical Center

Division name

Division of Infectious Diseases and Infection Control

Zip code

3501298

Address

1397-1, Yamane, Hidaka City, Saitama, Japan

TEL

0429844111

Email

kmitsuta@saitama-med.ac.jp


Public contact

Name of contact person

1st name Natsuki
Middle name
Last name Shinya

Organization

Saitama Medical University International Medical Center

Division name

Infection Control Center

Zip code

3501298

Address

1397-1, Yamane, Hidaka City, Saitama, Japan

TEL

0429844111

Homepage URL


Email

ns92671@5931.saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical University International Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saitama Medical University International Medical Center IRB

Address

1397-1, Yamane, Hidaka City, Saitama, Japan

Tel

0429844523

Email

chikens@saitama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 08 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

65

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 03 Month 06 Day

Date of IRB

2019 Year 03 Month 06 Day

Anticipated trial start date

2019 Year 03 Month 06 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

-Study design: observational study (multi-institution study)
-Research period: Mar.6,2019 to Dec.31,2023
-Survey items:
Patient characteristics (age, sex, comorbidities, clinical complications, MRSA carriage, portal of entry)
Diagnosis (nosocomial or community-acquired, infected lesion, echocardiographic findings, MIC, duration of bacteremia)
Treatment (surgery performed or not, timing of surgery, antimicrobial selection, duration of antimicrobial therapy)
Prognosis (30days and in-hospital mortality)


Management information

Registered date

2023 Year 08 Month 17 Day

Last modified on

2023 Year 08 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059251


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name